Les bénéfices thérapeutiques d'un traitement systémique du rhumatisme psoriasique ? L'exemple du golimumab dans le rhumatisme psoriasique.
Boulinguez, Serge; Sibilia, Jean.
Ann Dermatol Venereol
; 138(5 Suppl 1): H11-5, 2011 May.
Artigo em Francês | MEDLINE | ID: mdl-21703459
Differing local and systemic inflammatory burden in polyarticular psoriatic arthritis and rheumatoid arthritis patients on anti-TNF treatment in clinical remission.
Disease activity states of the DAPSA, a psoriatic arthritis specific instrument, are valid against functional status and structural progression.
From inhibition of radiographic progression to maintaining structural integrity: a methodological framework for radiographic progression in rheumatoid arthritis and psoriatic arthritis clinical trials.
Ultrasound-integrated tight control in early psoriatic arthritis during adalimumab treatment.
Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT).
Swollen joint count in psoriatic arthritis is associated with progressive radiological damage in hands and feet.
Sonozaki syndrome: case report and review of literature.
No overall damage progression despite persistent inflammation in adalimumab-treated psoriatic arthritis patients: results from an investigator-initiated 48-week comparative magnetic resonance imaging, computed tomography and radiography trial.
The effects of structural damage on functional disability in psoriatic arthritis.
Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis.